Skip to content
value.today

iPierian, Inc.

Formerly iZumi Bio, Inc.

Total raised
$35 M
2 rounds on record
Latest round
$29 M
Jul 2010
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of iPierian, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2010$29 MNo. 2$10 to $50 million

iPierian, Inc.: Raise no. 2, Jul 2010

Investors in this round

20 investors had bought by the notice of Nov 9, 2010: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $29 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Stock, including the shares of Common Stock issuable upon conversion of the Series B Preferred Stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Berta J. Strulovici · Executive Officer · Vice President Research and Chief Technology Officer
  • Matthew J. Plunkett · Executive Officer · Vice President, Chief Financial Officer and Secretary
  • Michael Venuti · Executive Officer, Director · President, Chief Executive Officer and Chief Scientific Officer
  • Ashley L. Dombkowski · Director
  • Beth F. Seidenberg · Director
  • Corey S. Goodman · Director
  • Krishna F. Yeshwant · Director
  • Robert F. Higgins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Assistant Secretary. Source: SEC Form D and 2 amendments, newest notice filed Nov 9, 2010. Read the notice at the SEC.

equitySEC
Jul 2009$7 MNo. 1$2 to $10 million

iPierian, Inc.: Raise no. 1, Jul 2009

Investors in this round

4 investors had bought by the notice of Jul 16, 2009: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $12 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A-2 Preferred Stock (including the shares of Common Stock issuable upon conversion of the Series A-2 Preferred Stock).
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Berta Strulovici · Executive Officer · Chief Technology Officer
  • Jamie Kole · Executive Officer · Chief Financial Officer and VP, Operations
  • John Walker · Executive Officer, Director · President and Chief Executive Officer
  • Ashley Dombkowski · Director
  • Beth Seidenberg · Director
  • Bob Higgins · Director
  • Corey Goodman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jamie Kole, Chief Financial Officer and VP, Operations. Source: SEC Form D, newest notice filed Jul 16, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • iPierian, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2010).

    SEC Form D · Nov 2010

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2010

That is all the official record says: iPierian, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of iPierian, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by iPierian, Inc.
NameRoleNamed in
Berta J. StruloviciVice President Research and Chief Technology OfficerNov 2010
Matthew J. PlunkettVice President, Chief Financial Officer and SecretaryNov 2010
Michael VenutiPresident, Chief Executive Officer and Chief Scientific OfficerNov 2010
Berta StruloviciChief Technology OfficerJul 2009
Jamie KoleChief Financial Officer and VP, OperationsJul 2009
John WalkerPresident and Chief Executive OfficerJul 2009
Ashley L. DombkowskiDirectorNov 2010
Beth F. SeidenbergDirectorNov 2010
Corey S. GoodmanDirectorNov 2010
Krishna F. YeshwantDirectorNov 2010
Michael VenutiPresident, Chief Executive Officer and Chief Scientific OfficerNov 2010
Robert F. HigginsDirectorNov 2010
Ashley DombkowskiDirectorJul 2009
Beth SeidenbergDirectorJul 2009
Bob HigginsDirectorJul 2009
Corey GoodmanDirectorJul 2009
John WalkerPresident and Chief Executive OfficerJul 2009